This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
TheStreet Rating

10 Best Life Sciences Stocks for 2014

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 life sciences stocks are rated highest by our methodology.

Equity Top: Life Sciences Tools & Services

Source: TheStreet Ratings

Best Investments for 2014

Life Sciences

Catch up on Jim Cramer's thinking over the last week about PPG's Mexico deal and the market's amazing run.
11/22/14 2:07PM
Cramer will be listening to conference calls next week but says a lot of the companies are better than their stocks.
11/21/14 8:25PM
The performance of the Nikkei 225 over the last 25 years suggests money printing creates bubbles that eventually break.
11/21/14 2:59PM
The company aims to grow its production by 50% this year, but things could change next year if the price of a barrel of crude averages less than $80.
11/21/14 2:03PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/21/14 6:00AM
The latest example: Reams of wrongheaded hedge-fund short plays off the Ebola crisis.
11/20/14 11:38AM
It's worth paying attention to these potential portfolio killers.
11/20/14 9:55AM
Beijing-based IT superstar Lenovo, despite a record of smooth expansion, stands to lose the most from China's slowdown in smartphone shipments. Here's why.
11/20/14 6:10AM
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
11/19/14 1:25PM
TheStreet highlights 3 stocks pushing the drugs industry lower today.
11/19/14 12:16PM
TheStreet highlights 3 stocks pushing the drugs industry higher today.
11/19/14 12:16PM
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
11/19/14 11:21AM
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
11/19/14 11:17AM
Housing construction is finally showing signs of recovery, but not because more Americans are buying homes.
11/19/14 10:34AM
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
11/19/14 9:38AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs